1. Home
  2. CRVS vs ARTNA Comparison

CRVS vs ARTNA Comparison

Compare CRVS & ARTNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVS
  • ARTNA
  • Stock Information
  • Founded
  • CRVS 2014
  • ARTNA 1905
  • Country
  • CRVS United States
  • ARTNA United States
  • Employees
  • CRVS 31
  • ARTNA N/A
  • Industry
  • CRVS Biotechnology: Pharmaceutical Preparations
  • ARTNA Water Supply
  • Sector
  • CRVS Health Care
  • ARTNA Utilities
  • Exchange
  • CRVS Nasdaq
  • ARTNA Nasdaq
  • Market Cap
  • CRVS 328.5M
  • ARTNA 356.4M
  • IPO Year
  • CRVS 2016
  • ARTNA 1996
  • Fundamental
  • Price
  • CRVS $3.92
  • ARTNA $33.24
  • Analyst Decision
  • CRVS Strong Buy
  • ARTNA
  • Analyst Count
  • CRVS 4
  • ARTNA 0
  • Target Price
  • CRVS $15.00
  • ARTNA N/A
  • AVG Volume (30 Days)
  • CRVS 786.0K
  • ARTNA 28.3K
  • Earning Date
  • CRVS 08-05-2025
  • ARTNA 08-04-2025
  • Dividend Yield
  • CRVS N/A
  • ARTNA 3.63%
  • EPS Growth
  • CRVS N/A
  • ARTNA 22.05
  • EPS
  • CRVS N/A
  • ARTNA 2.08
  • Revenue
  • CRVS N/A
  • ARTNA $109,294,000.00
  • Revenue This Year
  • CRVS N/A
  • ARTNA $7.82
  • Revenue Next Year
  • CRVS N/A
  • ARTNA $3.54
  • P/E Ratio
  • CRVS N/A
  • ARTNA $15.98
  • Revenue Growth
  • CRVS N/A
  • ARTNA 8.31
  • 52 Week Low
  • CRVS $1.75
  • ARTNA $29.45
  • 52 Week High
  • CRVS $10.00
  • ARTNA $41.29
  • Technical
  • Relative Strength Index (RSI)
  • CRVS 49.54
  • ARTNA 49.46
  • Support Level
  • CRVS $3.83
  • ARTNA $33.10
  • Resistance Level
  • CRVS $4.33
  • ARTNA $34.14
  • Average True Range (ATR)
  • CRVS 0.28
  • ARTNA 0.75
  • MACD
  • CRVS -0.03
  • ARTNA -0.04
  • Stochastic Oscillator
  • CRVS 21.74
  • ARTNA 49.18

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

About ARTNA Artesian Resources Corporation

Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.

Share on Social Networks: